子宫内膜癌的辅助治疗:何时以及选择什么

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2022-02-15 DOI:10.31083/j.ejgo4301018

M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni

{"title":"子宫内膜癌的辅助治疗:何时以及选择什么","authors":"M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni","doi":"10.31083/j.ejgo4301018","DOIUrl":null,"url":null,"abstract":"Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adjuvant treatment in endometrial cancer: when and what to choose\",\"authors\":\"M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni\",\"doi\":\"10.31083/j.ejgo4301018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.\",\"PeriodicalId\":11903,\"journal\":{\"name\":\"European journal of gynaecological oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of gynaecological oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/j.ejgo4301018\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4301018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症是发达国家最常见的妇科恶性肿瘤。治疗主要是手术治疗，但根据复发风险，手术后可能需要辅助治疗。这篇综述将重点关注2020年ESGO/ESTRO/ESP指南中提出的预后风险组，以及基于新分子标记物的正在进行的试验，这些试验将有助于获得更个性化的癌症药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Adjuvant treatment in endometrial cancer: when and what to choose

Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.